Licensor.=[G/U/Who/mit_edu.md]

PrincipalInvestigator.=[G/U/Who/solomon_shirley.md]

EffectiveDate.YMD=2020-01-01

IssueFee.$=$50,000

DMP.1.$=$50,000

DMP.2.$=$150,000

DMP.3.$=$500,000

DMP.4.$=$2,500,000

MAR.1.$=$40,000

MAR.2.$=$80,000

MAR.3.$=$160,000

MAR.4.$=$320,000

FieldOfUse.sec=Any and all uses, except no uses in humans.

LicenseIssueFee.sec=Licensee shall pay an up-front fee of {IssueFee.$} within 10 days of the Effective Date.

CodersNote=These repeat and overwrite elements from the form. See the form to see the originals.

DevelopmentMilestonePayment.1.sec=Third subject dosed in Phase 2 clinical trial: {DMP.1.$} 

DevelopmentMilestonePayment.2.sec=Submission of the first IND for a Licensed Product: {DMP.2.$}  

DevelopmentMilestonePayment.3.sec=FDA approval of a Licensed Product: {DMP.3.$}

DevelopmentMilestonePayment.4.sec=First Commercial Sale of a Licensed Product: {DMP.4.$}


MinimumAnnualRoyalty.1.sec=First full {_CY} after {_Effective_Date}: {MAR.1.$}

MinimumAnnualRoyalty.2.sec=Second through fourth full {_CY}s after {_Effective_Date}: {MAR.2.$}

MinimumAnnualRoyalty.3.sec=Fifth full {_CY} after {_Effective_Date} and each {_CY} thereafter until {_First_Commercial_Sale}:  {MAR.3.$}

MinimumAnnualRoyalty.4.sec=First {_CY} after {_First_Commercial_Sale} and each {_CY} thereafter: {MAR.4.$}

DiligenceMilestone.1.sec=Obtaining financing in an amount of at least $500,000 by 2023-03-31

DiligenceMilestone.2.sec=Nomination of a development candidate by 2023-06-30

DiligenceMilestone.3.sec=Initiation of GLP toxicity studies by 2023-09-30

DiligenceMilestone.4.sec=Submission of the first IND for a {_Licensed_Product} by {IND.SubmissionDate.YMD}

DiligenceMilestone.5.sec=First subject dosed in Phase 1 clinical trial by 2024-12-31


PatentChallenges.1.sec={PatentChallenges.1.Alt1.sec}

PatentEnforcement.Initiator.Licensee/Licensor={_Licensee}

GoverningLaw.sec={Law.State}


=[G/NVCA/2020/LifeScience-License-TermSheet/Form/0.md]
